Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2023New England Journal of Medicine

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMasahiro TsuboiRHRoy S. HerbstTJThomas John

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tsuboi et al. (2023) studied this question.

synapsesocial.com/papers/6941cf2d6ff23261fafbb7c7https://doi.org/10.1056/nejmoa2304594
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC2019 · 2,937 citations
  2. 2Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC2025 · 106 citations
  3. 3Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States2024 · 7 citations
  4. 4Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC2021 · 156 citations
  5. 5Adjuvant erlotinib versus observation after complete resection of <i>EGFR</i> -mutant NSCLC: Final overall survival results of Alliance A081105.2026 · 1 citations